Remodulin and Deafness permanent - a phase IV clinical study of FDA data

Summary:

We study 56,030 people who take Remodulin (treprostinil sodium) or have Deafness permanent. No report of Deafness permanent is found in people who take Remodulin.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Remodulin?

Remodulin has active ingredients of treprostinil sodium. It is often used in primary pulmonary hypertension. eHealthMe is studying from 55,842 Remodulin users. Check the latest studies of Remodulin.

What is Deafness Permanent?

Deafness permanent is found to be associated with 4 drugs and 62 conditions by eHealthMe. Check the latest studies of Deafness permanent.

On May, 24, 2026

No report is found.

Do you take Remodulin and have Deafness permanent?

- Check whether Deafness permanent is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Remodulin:

Remodulin (55,842 reports)

Browse all side effects of Remodulin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Deafness permanent:

Deafness permanent

Browse all the conditions that are associated with Deafness permanent:

Deafness permanent

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Remodulin) and Remodulin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.